The integration of CGM coupled with intense multiple daily insulin injections or continuous subcutaneous insulin infusion (insulin pump) is rapidly becoming part of the standard of care in the ambulatory setting for glycemic control, as recommended by the International Society of Pediatric and Adolescent Diabetes (ISPAD), the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).1–3. This evidence concerns the gene INS and diabetes mellitus.